Kornimate/medical-research-clean huggingface dataset:
vitamin c efficacy in reducing post operative pain

Conditions: Gallbladder Inflammation

Summary: opioids are the corner stone in the treatment of post operative pain. because of the several side effects of opiods, non-steroidal anti-inflammatory drugs are usually added postoperatively to decrease the total requirements of opioids. however, non steroidal anti-inflammatory drugs have side effects of their own. vitamin c, with virtually no side effects when used on short-term basis, has been shown to have promising analgesic effects in chronic pain and acute pain relief following orthopedic surgeries. the investigators propose to assess the role of a prophylactic single dose (2g) of vitamin c in reducing the intensity of pain and the consumption of opioids in patients undergoing laparoscopic cholecystectomy at aub-mc. all eligible patients undergoing laparoscopic cholecystectomy at aub-mc will be included in the study. patients will be randomized into two groups to receive either single dose oral vitamin c (2g) (study group) or identically looking placebo capsules (control group). both the patients and the investigation team will be blinded to the type of intervention. intraoperative anesthesia management will be similar for both groups. postoperative pain control will be achieved with patient controlled analgesia via a patient controlled morphine pump in both groups. at several time intervals and up to 24 hours postoperatively, the pain scores, morphine consumptions, nausea/vomiting scores, sedation scales, itching scales, and patient satisfaction scales will be obtained for all patients. also, the peak vitamin c concentration will be determined for each patient. patients demographics will be obtained and compared between both groups. the differences in pain scores, morphine consumptions, nausea/vomiting scores, and sedation, itching, and patient satisfaction scales will be compared between the two groups with the student-t test, the analysis of variance, the fisher exact test, and the kruskal-wallis test. the peak vitamin c plasma concentration will be correlated with the pain scores in each group using regression analysis. this study will provide relevant information on whether a single dose (2g) of vitamin c can reduce morphine requirements and non steroidal anti-inflammatory drugs need and thus eliminating their side effects in patients undergoing laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: * patients of both gender * between 18-75 years old * asa class i, ii, or iii * scheduled to undergo laparoscopic cholecystectomy exclusion criteria: * intake of anti-inflammatory drug in the past 24 hr * allergy to morphine * history of chemical dependence * chronic pain state * inability to use pca pumps * history of obstructive sleep apnea * history of severe asthma * history of copd * history of gastroesophageal reflux disease

Keywords: gallbladder removal acute cholecystitis laparoscopic cholecestectomy
randomized controlled trial of a community health worker program on hearing loss (oyendo bien)

Conditions: Hearing Loss

Summary: the purpose of this study is to test the effectiveness of a community health worker intervention to expand access to hearing health care among older adults facing health disparities.


Eligibility criteria:
inclusion criteria: * minimum age: 50 years * audiometrically-confirmed hearing loss * availability of a communication partner to attend the program with the participant * be spanish speaking and able to sign written informed consent exclusion criteria: * cognitive impairment
tissue oximetry's measurement in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Conditions: Oxygen Deficiency; Acute Kidney Injury; Ovarian Carcinoma

Summary: tissue oximetry obtained from peripheral muscle measures the state of tissue oxygenation of various organs and, as already widely described in the literature, can be used to measure the state of kidney's tissue oxygenation. however, there is no evidence in the existing scientific literature on the use of muscle tissue oximetry in patients undergoing cytoreductive surgery for ovarian cancer with hyperthermic intraperitoneal chemotherapy. the primary objective of our study is to evaluate whether there is a correlation between average intraoperative muscle tissue oximetry below 65% (a value which is considered critical in the literature for the resulting cellular damage) and postoperative renal damage in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancer.

tissue oximetry obtained from peripheral muscle can be used to measure the state of kidney's tissue oxygenation. 50 adult female patients asa 1-2 undergoing cytoreductive surgery with laparoscopic or laparotomy technique (for ovarian cancer) associated with hyperthermic intraperitoneal chemotherapy will be enrolled. the primary objective of our study is to evaluate whether there is a correlation between average intraoperative muscle tissue oximetry below 65% (a value which is considered critical in the literature for the resulting cellular damage) and postoperative renal damage (according to the akin and kidgo classification) in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for ovarian cancer. secondary objectives are: * describe the variation in muscle tissue oximetry and hemodynamic parameters (systolic, mean, diastolic blood pressure) during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy . * describe the variation in renal function values (blood urea nitrogen, creatinine) and serum electrolytes (sodium, potassium, chloremia, calcemia) in the post-operative period (from the first to the seventh postoperative day).

Eligibility criteria:
inclusion criteria: * american society anesthesiologists (asa) classification 1-2 * cytoreductive surgery for ovarian cancer with laparoscopic or laparotomic technique with hypertermic intraperitoneal chemotherapy. exclusion criteria: * age \< 18 years * asa \> or = 3 * cytoreductive surgery without hyperthermic intraperitoneal chemotherapy

Keywords: tissue oximetry hyperthermic intraperitoneal chemotherapy acute kidney injury hemodynamics parameters
para-vertebral dexmedetomidine and the incidence of postoperative chronic pain

Conditions: Pain, Postoperative

Summary: up to our knowledge there is no study focused upon the incidence of post vats chronic pain when dexmedetomidine is used.

most video-assisted throcoscopy surgery (vats) procedures are considered low-risk interventions requiring short hospital stays or even outpatient settings. because of these factors, vats did not raise as much interest as thoracotomy in its postoperative pain management. however, it is a fact that pain following vats can be severe and long-lasting .according to richardson and colleagues, 38% of vats procedures present persistent pain two months after surgery as a result of acute nerve damage during the surgical procedure.

Eligibility criteria:
inclusion criteria: * asa ii-iii * adult * video-assisted thoracic surgery exclusion criteria: * patient refusal * allergy to medication * coagulopathy * malformation
safety and efficacy study of a protease activated receptor-4 antagonist being tested to reduce the chances of having additional strokes or "mini strokes"

Conditions: Thrombosis

Summary: the purpose of this study is to determine whether bms-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a tia or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or asa) to treat the stroke or tia.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * male or female, age 18 or older * must have had a very recent stroke or transient ischemic attack ("mini stroke") that can be confirmed by the study doctor * able to be assigned to a study group no later than 48 hours after the stroke occurred * has an image of the brain that confirms that the stroke was not caused by hemorrhage or other reason that could explain symptoms exclusion criteria: * a suspicion by the study doctor that the transient ischemic attack or stroke was caused by a blood clot that formed in the heart; examples of this include history of an abnormal heart rhythm known as atrial fibrillation or a ventricular aneurysm or defect of the heart. * any condition requiring treatment with an anticoagulant * history of intracranial hemorrhage ("bleeding in the brain") * gastrointestinal ("stomach or intestinal") bleeding in the last 3 months that required treatment * planned or anticipated invasive surgery or procedure during the study * unable to tolerate mri procedures.
hemoglobin a1c and immediate postsurgical complications diabetes type 2

Conditions: Postoperative Complications

Summary: the purpose of this study is to evaluate hemoglobin a1c values previous to a surgery in patients with diabetes type ii and the complication incidence in immediate post surgery.

the diabetes is a highly prevalent disease in patients who undergo an evaluation previous to a surgery. the most efficient glucose control, in patients with diabetes type ii, reduces the risk of microvascular complications. diabectic patients who underwent scheduled cardivacular or noncardiovascular surgeries show an increase rate of immediate and long-term complications. the most frequent complications are infections, cardiovascular events and death. intensive insulinisation during cardiovascular surgery reduces the risk of a new coronary event in the immediate post surgery. no studies have been found that show the evaluation of hemoglobin a1c values before the surgery and the immediate post surgery complications. a poor glycemic control has been associated to a large number of chronic complications like diabetic neuropathy, nephropathy, retinopathy and infection disease. the hemoglobin a1c is used like a marker of the glycemic control in the last 120 days and has a correlation with the no enzyme glicosilation. this marker could have a relation with the complication after the programmed surgery. this study will evaluate the incidence of complications in the immediate post operatory in patients with diabetes type ii in relation to the hemoglobin a1c before the surgery. if the hemoglobin a1c has a correlation with the incidence of cardiovascular complications, this could mark a change in the therapeutic measures prior the programmed surgery.

Eligibility criteria:
inclusion criteria 1. patients older than 18 years with diagnosed of diabetes type 2 2. programmed major surgery with expected hospitalization longer than 24 hours exclusion criteria 1. refusal to participate in the study or the informed consent process. 2. programmed cardiac or coronary surgery 3. technical complications inherent to surgical or anatomical abnormalities. 4. pregnant women. 5. active infection prior to performing surgery
effectiveness of oral alfacalcidol for secondary hyperparathyroidism in chronic hemodialysis patients.

Conditions: Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis

Summary: primary objective was to evaluate the efficacy between daily and pulse oral alfacalcidol treatment of shpt in chronic hemodialysis patients, a 12-week treatment. secondary objective was to observe the adverse effects between these two treatment regimens.

esrd patients with secondary hyperparathyroidism in 3 hemodialysis centers were enrolled. they were assigned to either oral daily or pulse (trice a week) alfacalcidol treatments using block-of-4 randomization. alfacalcidol in both groups were equal at the dose of 6 microgram per week. clinical and laboratory data were obtained at baseline and were monitored every 4 weeks for 12 weeks. primary outcome was the difference of the mean pth reduction between two groups at the end of the study by unpaired-t test. all possible adverse events were carefully monitored.

Eligibility criteria:
inclusion criteria: * age ≥ 18 y esrd on hd kt/v ≥ 3.6/wk 2˚hpt stable in p binder for 4 wk exclusion criteria: * alfacalcidol allergy serum ca ≥ 10.5 mg/dl serum p ≥ 5.5 mg/dl pregnancy on phenytoin, phenobarbital
a study on the safety of tak-279 and whether it can reduce inflammation in the bowel of participants with moderately to severely active crohn's disease

Conditions: Crohn's Disease

Summary: crohn's disease (cd) is a long-lasting condition causing inflammation that can affect any part of the gut. the purpose of this study is to evaluate the efficacy and safety of tak-279 versus placebo in participants with moderately to severely active crohn's disease (cd). the main aim of this study is to learn if the 3 different doses of tak-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. another aim is to compare any medical problems that participants have when they take tak-279 or placebo and how well the participants tolerate medical problems. an endoscopy will be used to check the bowel for inflammation. the participants will be treated with tak-279 for 52 weeks (1 year). during the study, participants will visit their study clinic 15 times.

the drug being tested in this study is tak-279. tak-279 is being tested to treat participants with moderately to severely active crohn's disease. the study will look at the efficacy and safety of tak-279. the study will enroll approximately 268 participants. during the induction period participants will be randomly assigned to one of the following treatment groups in a ratio of 1:1:1:1 to receive tak-279 or placebo which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need): 1. tak-279 dose 1 2. tak-279 dose 2 3. tak-279 dose 3 4. placebo this multi-center trial will be conducted globally. the overall study duration is approximately 60 weeks including a 4-week safety follow-up period.

Eligibility criteria:
inclusion criteria: 1. male or female aged 18-75 years old with diagnosis of cd for at least 30 days. in south korea, the age requirement for adult participants is \>=19 years of age. 2. confirmed diagnosis of moderately to severely active cd assessed by ses-cd and cdai. 3. participants must have had an inadequate response to, loss of response to, or intolerance to at least one or more conventional, biologic, or advanced therapy for cd. exclusion criteria: 1. participants with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, and/or ulcerative colitis. 2. have complications of cd that might require surgery during the study. 3. participants with a current ostomy. 4. participants who have failed 3 or more classes of advanced therapies.

Keywords: drug therapy latitude cd, latitude research program
validation of a diagnostic test for glucose-6-phosphate dehydrogenase (g6pd) deficiency in anti-coagulated blood

Conditions: G6PD Deficiency

Summary: the primary objective of the study is to assess the accuracy of the sd biosensor standard™ point-of-care (poc) g6pd test in measuring g6pd activity and classifying results compared to a reference assay and across repeated measurements in capillary samples.

cross-sectional diagnostic accuracy study with 250 volunteer participants. the clinic will recruit and consent adult study participants. clinic staff will draw venous blood and obtain finger stick capillary blood samples. clinic staff will perform the investigational sd biosensor standard™ g6pd test for glucose-6-phosphate dehydrogenase (g6pd) deficiency and a hemocue® hemoglobin test on finger stick capillary blood. an anti-coagulated venous blood sample will be sent to a clinical laboratory improvement amendments (clia) certified lab for g6pd reference testing by the gold standard assays: g6pd measurement by spectrophotometry using the pointe scientific g6pd reference assay and hemoglobin measurement by a hematology analyzer. individuals identified as g6pd deficient or intermediate by the reference test will be notified of their results by the clinic and referred to their physician for follow-up. this study includes a nested repeatability study and a nested sample stability study. in the nested repeatability study up to 20 consented participants will provide 4 additional finger stick samples. clinic staff will perform the sd biosensor standard™ g6pd test to assess the repeatability of the test in capillary blood over 8 g6pd and hemoglobin measurements on up to 3 different instruments. in the nested sample stability study up to 8 consented participants will provide an additional venous blood draw sample to be tested at additional time points to document stability of the samples over time when tested by the sd biosensor standard™ g6pd test.

Eligibility criteria:
inclusion criteria: * must communicate an understanding of the study protocol. * must be able to provide written consent to undergo screening and provide medical history. * participants must be afebrile and in general good health in the opinion of the investigator as determined by vital signs, medical history, and physical examination. * black/african-american, by self-report. exclusion criteria: * blood transfusion in the past 3 months by self-report

Keywords: g6pd deficiency
analysis of recurrence of intraductal papilloma treated with vacuum-assisted rotary excision

Conditions: Breast Cancer Surgery; Benign Breast Tumors

Summary: to study the postoperative recurrence of intraductal papillomas (idp) treated with ultrasound-guided vacuum-assisted excision (vae), and to investigate the effect of different lesion characteristics on recurrence.

106 patients with idp with or without atypical ductal hyperplasia (adh) treated with ultrasound-guided vae at zhongnan hospital of wuhan university from january 2020 to august 2024 were selected for the study, and the postoperative conditions of the patients were sorted out and followed up to analyze the characteristics of the lesions and to determine the relevant factors that affected the postoperative recurrence.

Eligibility criteria:
inclusion criteria: * idp was diagnosed pathologically after vae treatment * the tumor was a solitary lesion with the margin \>1cm from the nipple and the longest diameter of the tumor \<3cm * it was not associated with other breast diseases exclusion criteria: * previous ductal breast surgery * abnormal coagulation function or taking anticoagulant drugs .recent or current use of hormonal or psychotropic drugs.

Keywords: intraductal papilloma of the breast treatment vacuum-assisted rotational excision therapy
cardiovascular risk in growth hormone deficient young adult males after completing growth hormone therapy

Conditions: Growth Hormone Deficiency

Summary: the purpose of this study is to compare the cardiovascular risks of growth hormone deficient young adult males who have completed growth hormone therapy to healthy young adult males.

adults with growth hormone deficiency are at risk for cardiovascular disease. what age this begins is not known. the objectives of this study are to compare the following measurements between growth hormone deficient young males 3-7 years post completion of growth hormone treatment and age related healthy controls: 1. carotid artery imaging 2. metabolic and cardiac parameters 3. body composition measurements

Eligibility criteria:
growth hormone deficient inclusion criteria: * males, 18-25 years old * completed growth hormone therapy approximately 3-5 years prior to study enrollment * history of multiple pituitary hormone deficiencies or growth hormone stimulation test \<7 at initiation of growth hormone therapy healthy control inclusion criteria: * males, 18-25 years old * no confirmed endocrine diagnosis including diabetes and thyroid disorders * bmi - z-score within 2 sd of mean exclusion criteria: * known risk factors for cardiovascular disease (eg tobacco use, hypertension, diabetes) * family history of early cardiovascular disease (myocardial infarction or stroke \<55years of age) in first degree family members * any implanted device * medication known to interfere with glucose or lipid metabolism or to influence blood pressure * chronic organ illness (eg severe asthma, hepatic or nephritic conditions)
feasibility and efficacy of a digital mental health intervention for teen wildfire survivors

Conditions: Disaster; PTSD; Adolescent Behavior; Trauma; Anxiety; Stress

Summary: in october, 2017, northern california experienced devastating and historic wildfires. sonoma rises is an app designed for anyone who was impacted by this event and is intended to help survivors of disaster find their new normal. this study will assess the feasibility and efficacy of a self-help post-disaster mental health intervention delivered via a mobile app with a sample of teens who are experiencing post-disaster mental health symptoms.


Eligibility criteria:
inclusion criteria: 1. males \& females aged 13-17 years directly impacted by the 2017 wildfires having lost their home or been temporarily displaced 2. screen positive for ptsd (child trauma screening questionnaire = 5 or higher) 3. have regular access to a smart phone and a computer 4. have a personal email address 5. speak and read english fluently 6. have parental consent exclusion criteria: 1. a positive self-reported history of psychosis, bipolar, or schizophrenia 2. serious self-reported physical health concerns necessitating surgery or with prognosis \<6 months 3. a positive screen for a current substance user disorder (crafft = 2 or higher) 4. current self-reported suicidal ideation 5. self-reported pregnancy 6. self-reported less than four weeks of stable prescription medication for anxiety, anti-depressant, and sleep promoting medications prior to the screening assessment

Keywords: mobile app disaster digital medicine teens